RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial of RL-007 These results support the progression of RL-007 to a double-blind, placebo-controlled Phase 2 trial focused on cognition NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) — atai Life Sciences…


Previous articleatai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
Next articlePT277 – Ryan Zurrer – Venture Capital, Reciprocity, and the Regenerative Financing Vine